IRIX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
IRIDEX Corp (IRIX) is not a strong buy for a beginner investor with a long-term strategy at this moment. While the company has shown some positive developments in revenue growth and product demand, the financial performance remains weak, with negative EPS and declining net income. The technical indicators and options data do not suggest a strong upward momentum, and there are no significant trading signals or catalysts to justify immediate investment.
The MACD is slightly positive and expanding, indicating mild bullish momentum. RSI is neutral at 54.558, and moving averages are converging, showing no clear trend. Key support is at 1.263, and resistance is at 1.401. The stock is currently trading near its pivot level of 1.332, suggesting limited immediate upside potential.
The company reported a 16% YoY revenue increase in Q4 2025, driven by strong demand in glaucoma and retina segments. Alliance Global initiated coverage with a Buy rating and a $3 price target, citing strong growth potential for its Cyclo G6 and PASCAL systems.
The company is assessing the impact of Middle East conflicts on product delivery schedules, which could lead to disruptions. Financial performance shows declining net income and EPS, with gross margin also decreasing YoY. No significant insider or hedge fund trading activity to indicate confidence.
Q4 2025 revenue was $14.7 million, up 16% YoY, but the company missed annual revenue targets with $52.7 million for 2025. Gross profit for Q4 was $5.5 million, showing improvement, but net income and EPS remain negative. Financials for 2025/Q3 showed declining net income (-18.62% YoY) and EPS (-25% YoY), with gross margin dropping to 32.15%.
Alliance Global initiated coverage with a Buy rating and a $3 price target, citing strong growth drivers in the company's product portfolio. However, no other recent analyst updates are available.
